# UroGen Pharma Ltd.: Phase 3 study completed, 99 enrolled (Bladder Cancer, Urothelial Carcinoma)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | UroGen Pharma Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer |
| NCT ID | NCT06331299 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder |
| Intervention types | drug |
| Target enrollment | 99 |
| Site countries | United States, Bulgaria, Estonia, Georgia, Latvia, Romania, Spain |
| Posted | 2024-03-26 |
| Planned start | 2024-08-29 |
| Event | Completed |
| Event date | 2026-09-15 |
| Last update posted | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06331299). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.